NCT06812559View on ClinicalTrials.gov

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2025

Conditions
Controlled Ovarian HyperstimulationPolycystic Ovarian Syndrome
Interventions
DRUG

Progesterone

compare the use of the progesterone-primed ovarian stimulation protocol versus GnRH antagonist protocol in women with polycystic ovarian syndrome (PCOS) regarding the number of oocytes retrieved, percentage of MII oocytes, and the rate of good quality blastocysts available for cryopreservation.

DRUG

GnRH antagonist (Cetrorelix)

Subcutaneous injection

Trial Locations (1)

21648

ELShatby University Hospital, Alexandria

All Listed Sponsors
lead

El Shatby University Hospital for Obstetrics and Gynecology

OTHER

NCT06812559 - Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome | Biotech Hunter | Biotech Hunter